
**CLAIMS:**

1. Use of an oligomeric compound having the following structure



,

or any pharmaceutical acceptable salts thereof,

in the manufacture of a medicament for the treatment or prevention of a disease or condition related to apo(a) and/or Lp(a) in a human, wherein from 75 mg to 85 mg of the oligomeric compound is to be administered to the human during a dosing period of one month.


2. The use according to claim 1, wherein the 75 mg to 85 mg of the oligomeric compound is to be administered to the human in not more than one unit dose.

3. The use according to claim 2, wherein 80 mg of the oligomeric compound is to be

administered to the human in not more than one unit dose.

4. The use according to claim 1, wherein 80 mg of the oligomeric compound is to be administered to the human during the dosing period.

5. Use of an oligomeric compound having the following structure




,

or any pharmaceutical acceptable salts thereof,

in the manufacture of a medicament for the treatment or prevention a disease or condition related to apo(a) and/or Lp(a) in a human, wherein 80 mg of the oligomeric compound is to be administered to a human once every month.

6. The use according to any one of claims 1-5, wherein the oligomeric compound is to be administered as a sodium salt.

7. The use according to any one of claims 1-6, wherein the oligomeric compound has the following structure:



8. The use according to any one of claims 1-7, wherein the human is at enhanced risk for cardiovascular events due to chronically elevated plasma Lp(a) levels.

9. The use according to any one of claims 1-8, wherein the disease or condition is selected from calcific aortic valve stenosis with elevated Lp(a), elevated cardiovascular risk with elevated Lp(a), recurrent cardiovascular events with elevated Lp(a), or one or more symptoms of a cardiovascular disease or disorder associated with elevated Lp(a).

10. The use according to any one of claims 1-9, wherein the oligomeric compound is to be administered to the human by injection.

11. The use according to claim 11, wherein the oligomeric compound is to be administered to the human by subcutaneous injection.

12. The use according to any one of claims 1-11, wherein the oligomeric compound is formulated in a sterile liquid.

13. The o use according to claim 12, wherein each unit dose of the oligomeric compound is not more than 1 mL, not more than 0.8 mL, not more than 0.5 mL, not more than 0.4 mL, not more than 0.25 mL, or not more than 0.2 mL of the sterile liquid.

14. The use according to claims 12 or 13, wherein:

(a) the sterile liquid is water,

(b) the sterile liquid is a physiologically compatible buffer,


(c) the sterile liquid is water with a sodium phosphate buffer, or

(d) the sterile liquid is water with a sodium phosphate buffer and sodium chloride.

15. The use according to any one of claims 12-14, wherein the oligomeric compound is present at a concentration of 100 mg/mL in a 0.8 mL solution.

16. The use according to any one of claims 1-15, wherein administration of the compound to a human reduces the fasting plasma Lp(a) concentration in the human by at least 50%, by at least 75%, by at least 80%, or by at least 85%, when the fasting plasma Lp(a) concentration in the human is measured at the start and end of the dosing period.

17. An oligomeric compound having the following structure



or any pharmaceutical acceptable salts thereof, for use in therapy.